Drug Shortage Report for TRIESENCE
| Report ID | 157590 |
| Drug Identification Number | 02368676 |
| Brand name | TRIESENCE |
| Common or Proper name | TRIESENCE 1ML SUSP. |
| Company Name | NOVARTIS PHARMACEUTICALS CANADA INC |
| Market Status | MARKETED |
| Active Ingredient(s) | TRIAMCINOLONE ACETONIDE |
| Strength(s) | 40MG |
| Dosage form(s) | SUSPENSION |
| Route of administration | INTRAVITREAL INTRAVITREAL |
| Packaging size | 1ML |
| ATC code | S01BA |
| ATC description | ANTIINFLAMMATORY AGENTS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2022-03-08 |
| Actual start date | 2022-04-12 |
| Estimated end date | 2025-02-15 |
| Actual end date | 2025-02-05 |
| Shortage status | Resolved |
| Updated date | 2025-02-06 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 700 RUE SAINT-HUBERT MONTREAL, QUEBEC CANADA H2Y 0C1 |
| Company contact information | [email protected] |
Version History
Click on "Compare" below to view the full report history and compare to other versions.